<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Dec 18)
Weinreich DM, Sivapalasingam S, et int., and Yancopoulos GD. [‚ÄúREGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.‚Äù](/search/?article=Weinreich20) _The New England journal of medicine_, 2020. [doi.org/10.1056/nejmoa2035002](https://doi.org/10.1056/nejmoa2035002). \[[PubMed33332778](https://www.ncbi.nlm.nih.gov/pubmed/33332778/)\]

### [Clinical Trials (Dec 17)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-17)

### Database Entries (Dec 17)
Eslami G, Mousaviasl S, et int., and Mobarak S. [‚ÄúThe impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.‚Äù](/search/?article=Eslami20) _Journal of Antimicrobial Chemotherapy_, 2020. [doi.org/10.1093/jac/dkaa331](https://doi.org/10.1093/jac/dkaa331). \[[PubMed32812051](https://www.ncbi.nlm.nih.gov/pubmed/32812051/)\] \[[PMC7529105](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529105/)\]
### Database Entries (Dec 16)
Hahn F, Wangen C, et int., and Marschall M. [‚ÄúIMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.‚Äù](/search/?article=Hahn20) _Viruses_, 2020. [doi.org/10.3390/v12121394](https://doi.org/10.3390/v12121394). \[[PubMed33291455](https://www.ncbi.nlm.nih.gov/pubmed/33291455/)\]
### Database Entries (Dec 16)
Painter WP, Holman W, et int., and Painter GR. [‚ÄúHuman Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2.‚Äù](/search/?article=Painter20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.10.20235747](https://doi.org/10.1101/2020.12.10.20235747).
### Database Entries (Dec 16)
Puhl AC, Fritch EJ, et int., and Ekins S. [‚ÄúRepurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.‚Äù](/search/?article=Puhl20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.01.407361](https://doi.org/10.1101/2020.12.01.407361). \[[PubMed33299990](https://www.ncbi.nlm.nih.gov/pubmed/33299990/)\] \[[PMC7724658](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724658/)\]
### Database Entries (Dec 16)
Cox RM, Wolf JD, and Plemper RK. [‚ÄúTherapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.‚Äù](/search/?article=Cox20) _Nature Microbiology_, 2020. [doi.org/10.1038/s41564-020-00835-2](https://doi.org/10.1038/s41564-020-00835-2). \[[PubMed33273742](https://www.ncbi.nlm.nih.gov/pubmed/33273742/)\]
### Database Entries (Dec 14)
Calistri A, Luganini A, et int., and Parolin C. [‚ÄúThe new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2.‚Äù](/search/?article=Calistri20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.06.412759](https://doi.org/10.1101/2020.12.06.412759).
### Database Entries (Dec 14)
Tree JA, Turnbull JE, et int., and Carroll MW. [‚ÄúUnfractionated heparin inhibits live wild‚Äêtype SARS‚ÄêCoV‚Äê2 cell infectivity at therapeutically relevant concentrations.‚Äù](/search/?article=Tree20) _British Journal of Pharmacology_, 2020. [doi.org/10.1111/bph.15304](https://doi.org/10.1111/bph.15304). \[[PubMed33125711](https://www.ncbi.nlm.nih.gov/pubmed/33125711/)\]

### Database Entries (Dec 11)
Abdelnabi R, Foo CS, et int., and Neyts J. [‚ÄúMolnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model.‚Äù](/search/?article=Abdelnabi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.10.419242](https://doi.org/10.1101/2020.12.10.419242).
### Database Entries (Dec 11)
Arabi YM, Shalhoub S, et int., and Fowler R. [‚ÄúRibavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.‚Äù](/search/?article=Arabi19)¬†_Clinical Infectious Diseases_,¬†2019.¬†[doi.org/10.1093/cid/ciz544](https://doi.org/10.1093/cid/ciz544).¬†\[[PubMed31925415](https://www.ncbi.nlm.nih.gov/pubmed/31925415/)\]¬†\[[PMC7108209](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108209/)\]
### Database Entries (Dec 11)
Hassan AO, Case JB, et int., and Diamond MS. [‚ÄúA SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.‚Äù](/search/?article=Hassan20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011). \[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\] \[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Database Entries (Dec 11)
Johnson RF, Bagci U, et int., and Marasco WA. [‚Äú3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.‚Äù](/search/?article=Johnson16) _Virology_, 2016. [doi.org/10.1016/j.virol.2016.01.004](https://doi.org/10.1016/j.virol.2016.01.004). \[[PubMed26828465](https://www.ncbi.nlm.nih.gov/pubmed/26828465/)\] \[[PMC4769911](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769911/)\]
### Database Entries (Dec 11)
Kawase M, Shirato K, et int., and Matsuyama S. [‚ÄúSimultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry.‚Äù](/search/?article=Kawase12) _Journal of Virology_, 2012. [doi.org/10.1128/jvi.00094-12](https://doi.org/10.1128/jvi.00094-12). \[[PubMed22496216](https://www.ncbi.nlm.nih.gov/pubmed/22496216/)\] \[[PMC3393535](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393535/)\]
### Database Entries (Dec 11)
Lu L, Liu Q, et int., and Jiang S. [‚ÄúStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.‚Äù](/search/?article=Lu14) _Nature Communications_, 2014. [doi.org/10.1038/ncomms4067](https://doi.org/10.1038/ncomms4067). \[[PubMed24473083](https://www.ncbi.nlm.nih.gov/pubmed/24473083/)\] \[[PMC7091805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091805/)\]
### Database Entries (Dec 11)
O'Keefe BR, Giomarelli B, et int., and McCray PB. [‚ÄúBroad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae.‚Äù](/search/?article=OKeefe10) _Journal of Virology_, 2009. [doi.org/10.1128/jvi.02322-09](https://doi.org/10.1128/jvi.02322-09). \[[PubMed20032190](https://www.ncbi.nlm.nih.gov/pubmed/20032190/)\] \[[PMC2820936](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820936/)\]
### Database Entries (Dec 11)
Vatansever EC, Yang K, et int., and Liu WR. [‚ÄúBepridil is potent against SARS-CoV-2 In Vitro.‚Äù](/search/?article=Vatansever20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.23.112235](https://doi.org/10.1101/2020.05.23.112235). \[[PubMed32511370](https://www.ncbi.nlm.nih.gov/pubmed/32511370/)\] \[[PMC7263498](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263498/)\]
### [Clinical Trials (Dec 10)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-10)

### Database Entries (Dec 09)
Sch√§fer A, Muecksch F, et int., and Sheahan TP. [‚ÄúAntibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.‚Äù](/search/?article=Schafer20) _Journal of Experimental Medicine_, 2020. [doi.org/10.1084/jem.20201993](https://doi.org/10.1084/jem.20201993). \[[PubMed33211088](https://www.ncbi.nlm.nih.gov/pubmed/33211088/)\] \[[PMC7673958](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673958/)\]
### Database Entries (Dec 09)
H√∂rnich BF, Gro√ükopf AK, et int., and Hahn AS. [‚ÄúSARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation and are not inhibited by Bromhexine.‚Äù](/search/?article=Hornich20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.25.221135](https://doi.org/10.1101/2020.07.25.221135).
### Database Entries (Dec 04)
Ar√©valo A, Pagotto R, et int., and Crispo M. [‚ÄúIvermectin reduces coronavirus infection in vivo: a mouse experimental model.‚Äù](/search/?article=Arevalo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.02.363242](https://doi.org/10.1101/2020.11.02.363242).
### Database Entries (Dec 04)
Clausen TM, Sandoval DR, et int., and Esko JD. [‚ÄúSARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.‚Äù](/search/?article=Clausen20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.033](https://doi.org/10.1016/j.cell.2020.09.033). \[[PubMed32970989](https://www.ncbi.nlm.nih.gov/pubmed/32970989/)\] \[[PMC7489987](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489987/)\]
### Database Entries (Dec 04)
Kumar R, Khandelwal N, et int., and Kumar N. [‚ÄúEmetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibitinginteraction of viral mRNAwith eIF4E: An in vitro study.‚Äù](/search/?article=Kumar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.29.401984](https://doi.org/10.1101/2020.11.29.401984).
### [Clinical Trials (Dec 03)](/page/updates/#clinical.trials)
[17 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-03)
### Database Entries (Dec 03)
Outlaw VK, Bovier FT, et int., and Porotto M. [‚ÄúInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.‚Äù](/search/?article=Outlaw20) _mBio_, 2020. [doi.org/10.1128/mbio.01935-20](https://doi.org/10.1128/mbio.01935-20). \[[PubMed33082259](https://www.ncbi.nlm.nih.gov/pubmed/33082259/)\] \[[PMC7587434](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587434/)\]
### Database Entries (Dec 03)
Udwadia ZF, Singh P, et int., and Tandon M. [‚ÄúEfficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.‚Äù](/search/?article=Udwadia20) _International Journal of Infectious Diseases_, 2020. [doi.org/10.1016/j.ijid.2020.11.142](https://doi.org/10.1016/j.ijid.2020.11.142). \[[PubMed33212256](https://www.ncbi.nlm.nih.gov/pubmed/33212256/)\] \[[PMC7668212](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668212/)\]

### [Published preprints - week of November 30](/page/updates/#published.preprints)
[Rosenke K](/search/?article=Rosenke20b);[Weisblum Y](/search/?article=Weisblum20);[Glasgow20](/search/?article=Glasgow20);[Xiao20](/search/?article=Xiao20);[Luban20](/search/?article=Luban20);[Liu20g](/search/?article=Liu20g)

### Database Entries (Nov 29)
de Melo GD, Lazarini F, et int., and Bourhy H. [‚ÄúAnti-COVID-19 efficacy of ivermectin in the golden hamster.‚Äù](/search/?article=Melo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.21.392639](https://doi.org/10.1101/2020.11.21.392639).
### Database Entries (Nov 29)
Schloer S, Brunotte L, et int., and Rescher U. [‚ÄúDrug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Schloer20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.16.342410](https://doi.org/10.1101/2020.10.16.342410).
### Database Entries (Nov 29)
Touret F, Driouich J, et int., and Nougair√®de A. [‚ÄúPreclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.‚Äù](/search/?article=Touret20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.17.386904](https://doi.org/10.1101/2020.11.17.386904).
### Database Entries (Nov 29)
Wang M, Zhao Y, et int., and Hu K. [‚ÄúTreatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial.‚Äù](/search/?article=Wang20n) _Clinical Infectious Diseases_, 2020. [doi.org/10.1093/cid/ciaa1417](https://doi.org/10.1093/cid/ciaa1417). \[[PubMed32955081](https://www.ncbi.nlm.nih.gov/pubmed/32955081/)\] \[[PMC7543328](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543328/)\]
### [Clinical Trials (Nov 26)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-26)
### Database Entries (Nov 26)
Simonovich VA, Burgos Pratx LD, et int., and Belloso WH. [‚ÄúA Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.‚Äù](/search/?article=Simonovich20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2031304](https://doi.org/10.1056/nejmoa2031304). [PubMed33232588](https://www.ncbi.nlm.nih.gov/pubmed/33232588/)
### Database Entries (Nov 25)
Busnadiego I, Fernbach S, et int., and Hale BG. [‚ÄúAntiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.‚Äù](/search/?article=Busnadiego20) _mBio_, 2020. [doi.org/10.1128/mbio.01928-20](https://doi.org/10.1128/mbio.01928-20). \[[PubMed32913009](https://www.ncbi.nlm.nih.gov/pubmed/32913009/)\] \[[PMC7484541](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484541/)\]
### Database Entries (Nov 25)
Jagannathan P, Andrews J, et int., and Singh U. [‚ÄúPeginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.‚Äù](/search/?article=Jagannathan20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.18.20234161](https://doi.org/10.1101/2020.11.18.20234161).

### Database Entries (Nov 24)
AlQahtani M, Abdulrahman A, et int., and Abduljalil M. [‚ÄúRandomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.‚Äù](/search/?article=AlQahtani20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.02.20224303](https://doi.org/10.1101/2020.11.02.20224303).
### Database Entries (Nov 24)
Bajpai M, Kumar S, et int., and Sarin SK. [‚ÄúEfficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.‚Äù](/search/?article=Bajpai20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.25.20219337](https://doi.org/10.1101/2020.10.25.20219337).
### Database Entries (Nov 24)
Fu L, Ye F, et int., and Gao GF. [‚ÄúBoth Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.‚Äù](/search/?article=Fu20d) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18233-x](https://doi.org/10.1038/s41467-020-18233-x). \[[PubMed32887884](https://www.ncbi.nlm.nih.gov/pubmed/32887884/)\] \[[PMC7474075](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474075/)\]
### Database Entries (Nov 24)
Hoffman RL, Kania RS, et int., and Taggart B. [‚ÄúDiscovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.‚Äù](/search/?article=Hoffman20) _Journal of Medicinal Chemistry_, 2020. [doi.org/10.1021/acs.jmedchem.0c01063](https://doi.org/10.1021/acs.jmedchem.0c01063). \[[PubMed33054210](https://www.ncbi.nlm.nih.gov/pubmed/33054210/)\] \[[PMC7571312](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571312/)\]
### Database Entries (Nov 24)
Joyner MJ, Bruno KA, et int., and Wright RS. [‚ÄúSafety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients‚Äù](/search/?article=Joyner20c) _Mayo Clinic Proceedings_, 2020. [doi.org/10.1016/j.mayocp.2020.06.028](https://doi.org/10.1016/j.mayocp.2020.06.028). \[[PubMed32861333](https://www.ncbi.nlm.nih.gov/pubmed/32861333/)\] \[[PMC7368917](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/)\]

### Database Entries (Nov 23)
Clementi N, Scagnolari C, et int., and Filippini A. [‚ÄúNaringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Clementi20b) _Pharmacological Research_, 2020. [doi.org/10.1016/j.phrs.2020.105255](https://doi.org/10.1016/j.phrs.2020.105255). \[[PubMed33096221](https://www.ncbi.nlm.nih.gov/pubmed/33096221/)\] \[[PMC7574776](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574776/)\]
### [Published preprints - week of November 23](/page/updates/#published.preprints)
[Rajter JC](/search/?article=Rajter20)
### Database Entries (Nov 23)
Doi Y, Hibino M, et int., and Kondo M. [‚ÄúA Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.‚Äù](/search/?article=Doi20b) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01897-20](https://doi.org/10.1128/aac.01897-20). \[[PubMed32958718](https://www.ncbi.nlm.nih.gov/pubmed/32958718/)\]
### Database Entries (Nov 23)
Libster R, Perez Marc G, et int., and Polack FP. [‚ÄúPrevention of severe COVID-19 in the elderly by early high-titer plasma.‚Äù](/search/?article=Libster20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.20.20234013](https://doi.org/10.1101/2020.11.20.20234013).
### Database Entries (Nov 23)
Shin YS, Lee JY, et int., and Park CM. [‚ÄúDiscovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.‚Äù](/search/?article=Shin20) _Bioorganic & Medicinal Chemistry Letters_, 2020. [doi.org/10.1016/j.bmcl.2020.127667](https://doi.org/10.1016/j.bmcl.2020.127667). \[[PubMed33160024](https://www.ncbi.nlm.nih.gov/pubmed/33160024/)\] \[[PMC7640924](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640924/)\]
### Database Entries (Nov 23)
Xiang Y, Nambulli S, et int., and Shi Y. [‚ÄúVersatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.‚Äù](/search/?article=Xiang20) _Science_, 2020. [doi.org/10.1126/science.abe4747](https://doi.org/10.1126/science.abe4747). \[[PubMed33154108](https://www.ncbi.nlm.nih.gov/pubmed/33154108/)\]
### [Press Release (Nov 22)](/page/updates/#press.release)
[Casirivimab and imdevimab EUA fact sheet for healthcare providers](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201122.pdf)
### Database Entries (Nov 20)
Andreano E, Nicastri E, et int., and Rappuoli R. [‚ÄúExtremely potent human monoclonal antibodies from convalescent Covid-19 patients.‚Äù](/search/?article=Andreano20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.07.328302](https://doi.org/10.1101/2020.10.07.328302).
### Database Entries (Nov 20)
Bracken CJ, Lim SA, et int., and Wells JA. [‚ÄúBi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.‚Äù](/search/?article=Bracken20) _Nature Chemical Biology_, 2020. [doi.org/10.1038/s41589-020-00679-1](https://doi.org/10.1038/s41589-020-00679-1). \[[PubMed33082574](https://www.ncbi.nlm.nih.gov/pubmed/33082574/)\]
### Database Entries (Nov 20)
Tortorici MA, Beltramello M, et int., and Veesler D. [‚ÄúUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.‚Äù](/search/?article=Tortorici20) _Science_, 2020. [doi.org/10.1126/science.abe3354](https://doi.org/10.1126/science.abe3354). \[[PubMed32972994](https://www.ncbi.nlm.nih.gov/pubmed/32972994/)\]

### [Clinical Trials (Nov 19)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-19)

### Database Entries (Nov 19)
Barnes CO, Jette CA, et int., and Bjorkman PJ. [‚ÄúSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.‚Äù](/search/?article=Barnes20b) _Nature_, 2020. [doi.org/10.1038/s41586-020-2852-1](https://doi.org/10.1038/s41586-020-2852-1). \[[PubMed33045718](https://www.ncbi.nlm.nih.gov/pubmed/33045718/)\]
### Database Entries (Nov 19)
Van Damme E, De Meyer S, et int., and Van Loock M. [‚ÄúIn Vitro Activity of Itraconazole Against SARS-CoV-2.‚Äù](/search/?article=Damme20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.13.381194](https://doi.org/10.1101/2020.11.13.381194).
### Database Entries (Nov 19)
Gendrot M, Andreani J, et int., and Pradines B. [‚ÄúIn Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.‚Äù](/search/?article=Gendrot20) _Molecules_, 2020. [doi.org/10.3390/molecules25215064](https://doi.org/10.3390/molecules25215064). \[[PubMed33142770](https://www.ncbi.nlm.nih.gov/pubmed/33142770/)\] \[[PMC7663271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663271/)\]
### Database Entries (Nov 19)
Wang S, Peng Y, et int., and Liu D. [‚ÄúCharacterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.‚Äù](/search/?article=Wang20l) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19568-1](https://doi.org/10.1038/s41467-020-19568-1). \[[PubMed33188207](https://www.ncbi.nlm.nih.gov/pubmed/33188207/)\] \[[PMC7666115](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666115/)\]

### [Published preprints - week of November 16](/page/updates/#published.preprints)
[Hurlburt NK](/search/?article=Hurlburt20) (_Nature Communications_); [Sacco MD](/search/?article=Sacco20) (_Science Advances_); [Zhang Q](/search/?article=Zhang20e) (_Cell Discovery_)
### Database Entries (Nov 17)
Monk PD, Marsden RJ, et int., and Rodrigues PM. [‚ÄúSafety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.‚Äù](/search/?article=Monk20) _The Lancet Respiratory Medicine_, 2020. [doi.org/10.1016/s2213-2600(20)30511-7](https://doi.org/10.1016/s2213-2600(20)30511-7). \[[PubMed33189161](https://www.ncbi.nlm.nih.gov/pubmed/33189161/)\]
### Database Entries (Nov 17)
Shi Y, Shuai L, et int., and Peng G. [‚ÄúThe Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract.‚Äù](/search/?article=Shi20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.12.380931](https://doi.org/10.1101/2020.11.12.380931).
